The US FDA has granted an Investigational Device Exemption (IDE) approval for MagicTouch Sirolimus Coated Balloon (SCB) indicated for In-Stent Restenosis (ISR).
US FDA's IDE approval allows the MagicTouch SCB to be used in a pivotal clinical study to support safety and effectiveness of this combination product. The data generated from this IDE clinical study will support a pre-market approval (PMA) application in the USA.
MagicTouch SCB is the world's first Sirolimus-coated Balloon with extensive commercial usage in Europe, major markets of Asia and the Mid-Eastern markets. More than 100 thousand patients have been treated with MagicTouch SCB in these markets.
About MagicTouch SCB:
MagicTouch SCB is a CE marked and commercially marketed Sirolimus coated balloon developed by Concept Medical, using proprietary Nanolute Technology. MagicTouch SCB has been used in >50,000 patients in major global markets.
About Concept Medical Inc (CMI):
CMI is headquartered in Tampa, Florida and has operational offices in The Netherlands, Singapore and Brazil and manufacturing units in India. CMI specializes in developing drug-delivery systems and has unique and patented technology platforms that can be deployed to deliver any drug / pharmaceutical agent across the luminal surfaces of blood vessels.
www.conceptmedical.com
Photo - https://mma.prnewswire.com/media/1901255/MagicTouch.jpg
Logo - https://mma.prnewswire.com/media/1244676/Concept_Medical_Logo.jpg
พลัส พร็อพเพอร์ตี้ โชว์ผลประกอบการครึ่งปีแรก ทะลุ 9 ร้อยล้าน! สะท้อนดีมานด์ Property Management โตต่อ เดินหน้าลุยบริการใหม่เสริมแกร่งธุรกิจ
"TPG X" ลงทุนร่วม "เลมอน-เอด" หัวแถวสตาร์ทอัพแพลตฟอร์มดิจิทัลรถยนต์มือสองเมืองไทย ตั้งเป้าไกลสู่อาเซียน